The FDA announced on June 29, 2022, that Glenmark Pharmaceuticals Inc., USA is recalling Telmisartan and Hydrochlorothiazide Tablets USP due to defective containers. The hazard involves difficult-to-open blisters and tablet breakage. Owners should contact the company for a remedy.
How to tell if you have it
- Brand: Glenmark
- Product: Telmisartan and Hydrochlorothiazide Tablets USP, 80 mg/25 mg, 30 Tablets, Rx Only
- NDC: 68462-842-13
- Lots: 17210935, 17210936 (Exp 05/2023), 17211206 (Exp 06/2023), 17211652, 17211655, 17211658 (Exp 08/2023)
- Distribution: nationwide
- Units: 72,288
The hazard
The recall was initiated due to complaints of difficult-to-open blisters and tablets breaking while opening the blister. The FDA classified this as a Class II recall.
Context
GovInfoNow's records show Glenmark Pharmaceuticals Inc., USA has had 54 other recalls since November 20, 2017. Recent Glenmark recalls include an Azelaic Acid Gel recall on July 23, 2026, for grainy texture risks and an Alyacen Birth Control Tablets recall on May 27, 2026, for impurities risk. Other recent recalls of similar products include Preferred Pharma's Ondansetron ODT recall due to defective seals (November 17, 2025), Harvard Drug Group's Midodrine tablets recall due to defective packaging (February 17, 2026), and an Oxycodone 5mg Tablets recall for weak blister seals (January 14, 2026).